PHARMACEUTICAL COMPOSITION OF RIFABUTIN FOR TREATING TUBERCULOSIS AND OTHER DISEASES MEDIATED BY HELICOBACTER PYLORI, METHOD OF PRODUCTION THEREOF AND METHOD FOR TREATMENT THEREOF

摘要

The present invention relates to medicine, pharmacy and nanotechnology, in particular, to a method of production (by nanoemulsion technique) of lyophilized rifabutin, solubilized by albumine, to a pharmaceutical composition for the treatment of tuberculosis and diseases mediated by Helicobacter pilory, where this pharmaceutical composition represents a lyophilized rifabutin, solubilized by albumine, and characterized by mean particle size from 4 to 10 nm, and after the addition of a pharmaceutically acceptable diluent or excipient, this pharmaceutical composition represents a physically stable solution, suitable for intravenous injection to a patient, where this solution also characterized by mean particle size from 4 to 10 nm, comprising intravenous injection of the pharmaceutical composition in a therapeutically effective amount to a patient in need thereof. According to the invention the pharmaceutical composition can be produced by a simpler and more available method free of polymers, making its clinical use more safety toxicologically.